MannKind (MNKD) News Today $3.71 -0.12 (-3.13%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.73 +0.02 (+0.54%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNKD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period MannKind (NASDAQ:MNKD) Upgraded by Wall Street Zen to "Buy" RatingWall Street Zen upgraded MannKind from a "hold" rating to a "buy" rating in a research note on Saturday.June 14 at 1:58 AM | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares of StockJune 11 at 6:48 AM | insidertrades.comBrokers Set Expectations for MannKind FY2026 EarningsJune 11 at 2:23 AM | americanbankingnews.comInsider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD)June 10, 2025 | gurufocus.comMannKind Co. (NASDAQ:MNKD) Director Sells 64,085 SharesMannKind Co. (NASDAQ:MNKD - Get Free Report) Director Steven B. Binder sold 64,085 shares of the firm's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $4.00, for a total transaction of $256,340.00. Following the sale, the director now owns 925,258 shares of the company's stock, valued at approximately $3,701,032. This represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.June 10, 2025 | marketbeat.comMannKind’s Strategic Growth Potential and Market Positioning: A Buy RecommendationJune 10, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Sets New 1-Year Low - Time to Sell?MannKind (NASDAQ:MNKD) Reaches New 12-Month Low - Should You Sell?June 10, 2025 | marketbeat.comCantor Fitzgerald Estimates MannKind FY2026 EarningsMannKind Co. (NASDAQ:MNKD - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of MannKind in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer forecasts that the biopharmaceutical company will pJune 10, 2025 | marketbeat.comMannKind Corp (MNKD) to Showcase Inhaled Insulin at ADA's 85th Scientific Sessions | MNKD stock newsJune 9, 2025 | gurufocus.comMannKind to present inhaled insulin study at ADA eventJune 9, 2025 | investing.comMannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23June 9, 2025 | globenewswire.comMannKind (NASDAQ:MNKD) Cut to Hold at Wall Street ZenJune 9, 2025 | americanbankingnews.comMannKind (NASDAQ:MNKD) Stock Rating Lowered by Wall Street ZenWall Street Zen cut shares of MannKind from a "buy" rating to a "hold" rating in a research report on Friday.June 7, 2025 | marketbeat.com180 Wealth Advisors LLC Has $11.04 Million Holdings in MannKind Co. (NASDAQ:MNKD)180 Wealth Advisors LLC boosted its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 4.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,194,704 shares of the biopharmaceutical company's stock afterJune 2, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Given Average Recommendation of "Buy" by BrokeragesShares of MannKind Co. (NASDAQ:MNKD - Get Free Report) have been assigned an average rating of "Buy" from the eight research firms that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation and two have issued a strong buy recomMay 31, 2025 | marketbeat.comINDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29May 27, 2025 | globenewswire.comVoloridge Investment Management LLC Has $6.86 Million Stake in MannKind Co. (NASDAQ:MNKD)Voloridge Investment Management LLC lowered its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 16.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,066,754 shares of the biopharmaceutical company'sMay 27, 2025 | marketbeat.comNuveen Asset Management LLC Lowers Stake in MannKind Co. (NASDAQ:MNKD)Nuveen Asset Management LLC cut its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,247,059 shares of the biophMay 27, 2025 | marketbeat.comTwo Sigma Advisers LP Boosts Stock Holdings in MannKind Co. (NASDAQ:MNKD)Two Sigma Advisers LP increased its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 16.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,092,627 shares of the biopharmaceutical company's stock after buyingMay 24, 2025 | marketbeat.comTwo Sigma Investments LP Boosts Stock Holdings in MannKind Co. (NASDAQ:MNKD)Two Sigma Investments LP raised its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 4.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,174,164 shares of the biopharmaceutical company's stock afMay 24, 2025 | marketbeat.comMan Group plc Purchases 219,891 Shares of MannKind Co. (NASDAQ:MNKD)Man Group plc boosted its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 61.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 578,310 shares of the biopharmaceutical company's stock after buying an additionMay 24, 2025 | marketbeat.comMillennium Management LLC Has $22.17 Million Stake in MannKind Co. (NASDAQ:MNKD)Millennium Management LLC raised its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 108.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,447,392 shares of the biopharmaceutical company's stoMay 23, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Acquired by Deutsche Bank AGDeutsche Bank AG grew its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 17.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 509,738 shares of the biopharmaceutical company's stock after purchasingMay 23, 2025 | marketbeat.comBank of America Corp DE Raises Position in MannKind Co. (NASDAQ:MNKD)Bank of America Corp DE lifted its holdings in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 29.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,364,313 shares of the biopharmaceutical company's stock after puMay 22, 2025 | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) EVP Sells 2,345 Shares of StockMay 21, 2025 | insidertrades.comNomura Holdings Inc. Sells 2,792,237 Shares of MannKind Co. (NASDAQ:MNKD)Nomura Holdings Inc. lowered its holdings in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 94.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 161,959 shares of the biopharmaceutical company's stock after selliMay 21, 2025 | marketbeat.comMannKind Stockholders Approve Board and CompensationMay 19, 2025 | tipranks.comDavid Thomson Sells 32,179 Shares of MannKind Co. (NASDAQ:MNKD) StockMay 16, 2025 | insidertrades.comMannKind Co. (NASDAQ:MNKD) Stake Lowered by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC cut its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 5.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,126,727 shares of the biopharmaceutical company'sMay 16, 2025 | marketbeat.comCantor Fitzgerald Expects Stronger Earnings for MannKindMannKind Co. (NASDAQ:MNKD - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for MannKind in a research report issued to clients and investors on Monday, May 12th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaMay 16, 2025 | marketbeat.comBNP Paribas Financial Markets Boosts Stock Position in MannKind Co. (NASDAQ:MNKD)BNP Paribas Financial Markets lifted its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 66.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 783,474 shares of the biopharMay 16, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Purchased by Northern Trust CorpNorthern Trust Corp boosted its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 8.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,777,784 shares of the biopharmaceutical company's stock after acquiring anMay 16, 2025 | marketbeat.comMannKind corp director Steven Binder sells $375,875 in stockMay 15, 2025 | investing.comMannKind EVP David Thomson sells shares worth $150,597May 15, 2025 | investing.comD. E. Shaw & Co. Inc. Has $27.45 Million Holdings in MannKind Co. (NASDAQ:MNKD)D. E. Shaw & Co. Inc. grew its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 23.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,269,063 shares of the biopharmaceMay 14, 2025 | marketbeat.comMannKind to Present at Upcoming Investor ConferencesMay 13, 2025 | globenewswire.comPromising Clinical Data and Market Potential Drive Buy Rating for MannKind’s AfrezzaMay 12, 2025 | tipranks.comGraham Capital Management L.P. Makes New Investment in MannKind Co. (NASDAQ:MNKD)Graham Capital Management L.P. acquired a new stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,590,761 shares of the biMay 12, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Sold by Tudor Investment Corp ET ALTudor Investment Corp ET AL reduced its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 45.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,382 shares of the biopharmaceutical companMay 11, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 855,261 Shares of MannKind Co. (NASDAQ:MNKD)Dimensional Fund Advisors LP increased its holdings in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 40.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,958,219 shares of the biopharmaceutical company'sMay 10, 2025 | marketbeat.comMannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comSchonfeld Strategic Advisors LLC Trims Stock Position in MannKind Co. (NASDAQ:MNKD)Schonfeld Strategic Advisors LLC decreased its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 80.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 237,660 shares of the biopharmaceutical company's stock after selling 1,May 9, 2025 | marketbeat.comDecoding MannKind Corp (MNKD): A Strategic SWOT InsightMay 9, 2025 | gurufocus.comMannKind’s Promising Growth and Strategic Advancements Justify Buy RatingMay 8, 2025 | tipranks.comMannKind Corporation (MNKD) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comMannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comMannKind Q1 2025 Earnings PreviewMay 7, 2025 | msn.comFreestone Grove Partners LP Makes New Investment in MannKind Co. (NASDAQ:MNKD)Freestone Grove Partners LP purchased a new stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 56,332 shares of the biopharmaceutical company's stock, valued at appMay 7, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from AnalystsMannKind Co. (NASDAQ:MNKD - Get Free Report) has earned an average rating of "Buy" from the nine analysts that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the compMay 6, 2025 | marketbeat.comMannKind (MNKD) to Release Earnings on ThursdayMannKind (NASDAQ:MNKD) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-mannkind-co-stock/)May 5, 2025 | marketbeat.com Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Media Mentions By Week MNKD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNKD News Sentiment▼0.630.88▲Average Medical News Sentiment MNKD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNKD Articles This Week▼175▲MNKD Articles Average Week Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alkermes News BioCryst Pharmaceuticals News Ligand Pharmaceuticals News Amicus Therapeutics News Celldex Therapeutics News Innoviva News Dynavax Technologies News Novavax News OPKO Health News Geron News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNKD) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MNKD Stock Free MNKD Stock Alerts